Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial
Gastroenterology(2015)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要